Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| novineon CRO GmbH | UNKNOWN |
Not provided
Not provided
Not provided
Endoscopic full-thickness resection (EFTR) is a therapeutic option for the treatment of challenging lesions such as subepithelial tumors (SETs) and epithelial neoplasia extending deeper than the mucosa or associated with significant fibrosis. EFTR may offer a less invasive treatment alternative relative to surgical approaches in selected patients.
The gastroduodenal FTRD System (gdFTRD System) is an instrument for endoscopic full-thickness resection or deep partial wall resection and diagnostic tissue acquisition through removal of suitable lesions in the stomach and duodenum.
The prospectively generated data of the gdFTRD registry shall be used to evaluate the application of the gdFTRD in clinical routine, to verify the acceptability of already known risks and to identify unknown risks and complications.
The gdFTRD registry is a registry on cases completed with the gdFTRD System. The gdFTRD System is used for full-thickness resection but the procedure is not part of the study. Only data processing is conducted within the study. For data processing, an EDC system is used.
There are no patient reported outcomes, only physician-entered data on baseline, intervention/procedure, complications/adverse events and follow-up visits.
Automatic plausibility checks have been programmed for quality assurance. Furthermore, warnings and hints will be given on predefined entries not allowed or to double-check values out of normal ranges. No source data verification is planned but data management will check the entries for completeness.
No coding according to MEDRA or similar systems is planned. As the procedure is not part of the study, every participating site must operate according to their own SOPs. The sponsor and CRO have SOPs in place for conducting a study. Furthermore, data protection requirements and all applicable regulations are followed.
The sample size was calculated based results of peer-reviewed publications on the gdFTRD System. As only continuous and categorial variables will be assessed, no separate statistical analysis plan is planned. In case the collected data allows for exploratory post hoc subgroup analysis further tests can be done according to the descriptions in the protocol. Missing data will not be included in the analysis and shall not be imputed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| All patients of legal age with given informed consent to data processing | All patients of legal age in whom the gdFTRD was used for treatment independently from the registry |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Data processing only, treatment is not part of the registry | Other | Treatment with the gdFTRD is part of the clinical routine, the registry only comprises data processing after treatment. |
| Measure | Description | Time Frame |
|---|---|---|
| Technical success | Technical success (i.e. target lesion reached and resected; macroscopically complete) | Directly post-procedure |
| Measure | Description | Time Frame |
|---|---|---|
| Full thickness resection | Full-thickness resection (i.e. histologically confirmed full-thickness resection) | Up to 14 days post-procedure |
| R0 resection | R0 resection (i.e. histologically complete lesion resection) |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of procedure-related adverse events (Safety) | Total procedure-related adverse events | Intra-procedural and directly post-procedure |
| Incidence of surgery due to procedure-related adverse events (Safety) |
Inclusion criteria:
Exclusion criteria:
Not provided
Not provided
Not provided
All patients of legal age in whom the gdFTRD was used for treatment independently from the registry.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Bettina Stritzke | Contact | +49 707196528-174 | bettina.stritzke@ovesco.com | |
| Marc O. Schurr, Prof. Dr. | Contact | +49 707196528-121 | marc.schurr@ovesco.com |
| Name | Affiliation | Role |
|---|---|---|
| Andreas Wannhoff, PD Dr. med. | RKH Kliniken Ludwigsburg-Bietigheim gGmbH | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Universitätsklinikum Freiburg - Klinik für Innere Medizin II | Freiburg im Breisgau | Germany | 79106 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41647622 | Background | Nabi Z, Basha J, Inavolu P, Sayyed M, Ramchandani M, Goud R, Darisetty S, Kotla R, Reddy DN. Exposed versus nonexposed endoscopic full-thickness resection for duodenal subepithelial lesions: a tertiary care center experience (with videos). IGIE. 2023 May 19;2(2):154-160.e2. doi: 10.1016/j.igie.2023.04.004. eCollection 2023 Jun. | |
| 33015330 |
Not provided
Not provided
Anonymized data will be used for publication of all participant data.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000236 | Adenoma |
| ID | Term |
|---|---|
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| Up to 14 days post-procedure |
| Rate of curative resection (in case of malignant tumors) | Rate of curative resection (in case of malignant tumors) | Up to 14 days post-procedure |
Surgery due to a procedure-related adverse event
| up to 2 weeks post-procedure |
| Incidence of post-interventional complications (Safety) | Post-interventional complications | up to 2 weeks post-procedure |
| Incidence of further procedure-related complications (Safety) | Other procedure-related complications | up to 3 years post-procedure |
| RKH Kliniken Ludwigsburg-Bietigheim gGmbH | Ludwigsburg | Germany | 71640 | Germany |
| Robert-Bosch-Krankenhaus | Stuttgart | Germany | 70376 | Germany |
|
| Hajifathalian K, Ichkhanian Y, Dawod Q, Meining A, Schmidt A, Glaser N, Vosoughi K, Diehl DL, Grimm IS, James T, Templeton AW, Samarasena JB, Chehade NEH, Lee JG, Chang KJ, Mizrahi M, Barawi M, Irani S, Friedland S, Korc P, Aadam AA, Al-Haddad M, Kowalski TE, Smallfield G, Ginsberg GG, Fukami N, Lajin M, Kumta NA, Tang SJ, Naga Y, Amateau SK, Kasmin F, Goetz M, Seewald S, Kumbhari V, Ngamruengphong S, Mahdev S, Mukewar S, Sampath K, Carr-Locke DL, Khashab MA, Sharaiha RZ. Full-thickness resection device (FTRD) for treatment of upper gastrointestinal tract lesions: the first international experience. Endosc Int Open. 2020 Oct;8(10):E1291-E1301. doi: 10.1055/a-1216-1439. Epub 2020 Sep 22. |
| 40079474 | Background | Wannhoff A, Nabi Z, Moons LMG, Haber G, Ge PS, Dertmann T, Deprez PH, Korcz W, Bouvette C, Mueller J, Tribonias G, Grande G, Kim JJ, Weich A, Heinrich H, Mollenkopf M, George J, Pioche M, Azzolini F, Kouladouros K, Boger P, Hayee B, Bilal M, Bastiaansen BAJ, Caca K; Upper GI FTRD Study Group. International, Multicenter Analysis of Endoscopic Full-Thickness Resection of Duodenal Neuroendocrine Tumors. Am J Gastroenterol. 2025 Dec 1;120(12):2800-2809. doi: 10.14309/ajg.0000000000003409. Epub 2025 Mar 13. |
| 31187233 | Background | Meier B, Schmidt A, Glaser N, Meining A, Walter B, Wannhoff A, Riecken B, Caca K. Endoscopic full-thickness resection of gastric subepithelial tumors with the gFTRD-system: a prospective pilot study (RESET trial). Surg Endosc. 2020 Feb;34(2):853-860. doi: 10.1007/s00464-019-06839-2. Epub 2019 Jun 11. |